Developer docs
API playgroundTry for free, no card

Search company profiles

NantKwest

Full company profile

uuid0005uoc

Namestring
NantKwest
Legal namestring
ImmunityBio, Inc.
Websiteurl
nantkwest.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

ImmunityBio, Inc., operating under the legacy NantKwest trademark, is a clinical-stage biopharmaceutical company within the NantWorks conglomerate that develops immunotherapy products for cancer and infectious diseases. The company's core technology is a Natural Killer (NK) cell platform built on the NK-92 cell line, encompassing four proprietary variants (haNK, taNK, ceNK, and the NK-92 line itself) combined with ANKTIVA® (nogapendekin alfa inbakicept), an IL-15 superagonist that stimulates NK cells, T cells, macrophages, and dendritic cells to drive both innate and adaptive immune responses. ANKTIVA is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ, and a supplemental BLA for papillary disease carries a PDUFA date of January 6, 2027. The QUILT clinical framework coordinates combination regimens across bladder cancer (QUILT-3.032, QUILT-2.005), NSCLC (ResQ201A), and other indications.

The business model is anchored on commercializing ANKTIVA as a combination therapy with BCG for bladder cancer, supported by an exclusive U.S. supply agreement with Japan BCG Laboratory for the Tokyo-strain BCG. Revenue mechanics include direct physician and clinical-site distribution for approved indications, expanded access and clinical trial enrollment, and a cell licensing program for the NK cell platform targeting academic and industry researchers. The company serves healthcare providers, clinical trial investigators, and patient populations across bladder cancer, glioblastoma, Lynch syndrome, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, HIV, HPV, and lymphopenia. Globally, the company currently operates in the United States, with no disclosed non-U.S. commercial footprint. Ownership rests within the NantWorks ecosystem founded by Dr. Patrick Soon-Shiong, who serves as Global Chief Scientific and Medical Officer.

Short descriptiontext

ImmunityBio, a NantWorks-affiliated biopharmaceutical company, develops NK cell-based immunotherapies for cancer and infectious diseases, with FDA-approved ANKTIVA used with BCG for BCG-unresponsive non-muscle invasive bladder cancer and a broader clinical pipeline across multiple tumor types.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCulver City, United States
HQ citystring
Culver City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
immunotherapy drug development, natural killer cell therapy, IL-15 superagonist biologic, bladder cancer treatment, oncology clinical trials
Industry4 codes
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Immunotherapy
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 11 records shown
1ANKTIVA®
Description

FDA-approved immunotherapy product (nogapendekin alfa inbakicept) used with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

immunitybio.com
+10 more records
Core offering1 text field

ImmunityBio (operating under the NantKwest trademark) develops and commercializes immunotherapies for cancer and infectious diseases. Its lead product ANKTIVA (nogapendekin alfa inbakicept) is an IL-15 superagonist FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ, combined with BCG. The company also advances investigational NK-cell platforms (haNK, taNK, ceNK, NK-92), QUILT combination clinical programs, and the Nant Cancer Vaccine candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • FDA PDUFA date set for January 6, 2027 for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary disease
Product overview1 text field

ImmunityBio (operating under the NantKwest trademark) is a biopharmaceutical company developing immunotherapies through a platform approach. The core product is ANKTIVA® (nogapendekin alfa inbakicept), an IL-15 superagonist that activates both innate (NK cells) and adaptive (T cells) immune responses. This is combined with BCG (including an exclusive Tokyo-strain agreement) in their QUILT clinical programs for bladder cancer. The company also operates an investigational NK Cell Platform (haNK, taNK, ceNK) derived from the NK-92 cell line. The platform employs a 'triangle offense' strategy targeting multiple immune pathways to achieve durable responses in cancer and infectious diseases.

Product and service6 records
1ANKTIVA (nogapendekin alfa inbakicept)
CategoryBiologic immunotherapy (IL-15 superagonist)
Description

An IL-15 superagonist biologic that activates natural killer (NK) cells and CD8+ T cells to stimulate innate and adaptive immune responses; FDA-approved for use with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ, and intended for oncology and infectious disease indications.

2NK Cell Platform (haNK, taNK, ceNK, NK-92)
CategoryCell therapy platform
Description

A suite of investigational Natural Killer cell therapy agents — high-affinity (haNK), targeted (taNK), cord blood-derived (ceNK), and the parent NK-92 cell line — designed to enhance innate immune responses against cancer and being investigated across multiple tumor types.

3QUILT Clinical Program Platform
CategoryClinical development program
Description

Clinical trial platform combining ANKTIVA with BCG, checkpoint inhibitors, and other agents to evaluate sequential immunotherapy regimens across NMIBC, NSCLC, glioblastoma, lymphoma, ovarian cancer, and other indications.

4Cell Licensing (NK cell lines to researchers)
CategoryResearch licensing
Description

Licensing of proprietary NK cell lines (haNK, taNK, ceNK, NK-92) to academic and industry researchers for use in independent immuno-oncology research programs.

5Tokyo-Strain BCG Supply (exclusive U.S. agreement with Japan BCG Laboratory)
CategoryCombination therapeutic supply
Description

Exclusive U.S. supply of the Tokyo strain of BCG from Japan BCG Laboratory, used as part of ANKTIVA plus BCG combination therapy for bladder cancer to enhance BCG supply in the United States.

6Nant Cancer Vaccine (NANT 001, NANT XL)
CategoryTherapeutic vaccine
Description

Cancer vaccine product candidates (including NANT 001 and NANT XL) under development by ImmunityBio as part of its immunotherapy pipeline targeting multiple cancer indications.

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ImmunityBio signed an exclusive U.S. agreement with Japan BCG Laboratory for the Tokyo-strain of BCG to enhance BCG supply in the United States. This partnership addresses supply chain needs for their ANKTIVA plus BCG combination therapy for bladder cancer.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment8 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NantKwest

Biopharmaceutical Immunotherapynantkwest.com

ImmunityBio, a NantWorks-affiliated biopharmaceutical company, develops NK cell-based immunotherapies for cancer and infectious diseases, with FDA-approved ANKTIVA used with BCG for BCG-unresponsive non-muscle invasive bladder cancer and a broader clinical pipeline across multiple tumor types.

What NantKwest does

ImmunityBio, Inc., operating under the legacy NantKwest trademark, is a clinical-stage biopharmaceutical company within the NantWorks conglomerate that develops immunotherapy products for cancer and infectious diseases. The company's core technology is a Natural Killer (NK) cell platform built on the NK-92 cell line, encompassing four proprietary variants (haNK, taNK, ceNK, and the NK-92 line itself) combined with ANKTIVA® (nogapendekin alfa inbakicept), an IL-15 superagonist that stimulates NK cells, T cells, macrophages, and dendritic cells to drive both innate and adaptive immune responses. ANKTIVA is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ, and a supplemental BLA for papillary disease carries a PDUFA date of January 6, 2027. The QUILT clinical framework coordinates combination regimens across bladder cancer (QUILT-3.032, QUILT-2.005), NSCLC (ResQ201A), and other indications.

The business model is anchored on commercializing ANKTIVA as a combination therapy with BCG for bladder cancer, supported by an exclusive U.S. supply agreement with Japan BCG Laboratory for the Tokyo-strain BCG. Revenue mechanics include direct physician and clinical-site distribution for approved indications, expanded access and clinical trial enrollment, and a cell licensing program for the NK cell platform targeting academic and industry researchers. The company serves healthcare providers, clinical trial investigators, and patient populations across bladder cancer, glioblastoma, Lynch syndrome, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, HIV, HPV, and lymphopenia. Globally, the company currently operates in the United States, with no disclosed non-U.S. commercial footprint. Ownership rests within the NantWorks ecosystem founded by Dr. Patrick Soon-Shiong, who serves as Global Chief Scientific and Medical Officer.

NantKwest firmographics

Firmographics
Name
NantKwest
Legal name
ImmunityBio, Inc.
Website
https://nantkwest.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
ImmunityBio, a NantWorks-affiliated biopharmaceutical company, develops NK cell-based immunotherapies for cancer and infectious diseases, with FDA-approved ANKTIVA used with BCG for BCG-unresponsive non-muscle invasive bladder cancer and a broader clinical pipeline across multiple tumor types.
Ownership category
akta.pro rank

NantKwest industry classification

Industry
Product category
Biopharmaceutical Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Immunotherapy drug development
  • Natural killer cell therapy
  • IL-15 superagonist biologic
  • Bladder cancer treatment
  • Oncology clinical trials

Where NantKwest is headquartered

Location

Headquarters

HQ city
Culver City
HQ country
United States
HQ region
North America

Markets served

NantKwest business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Distribution channels1 record

Marketing channels4 records

NantKwest product offering

Product offering

Core offering

ImmunityBio (operating under the NantKwest trademark) develops and commercializes immunotherapies for cancer and infectious diseases. Its lead product ANKTIVA (nogapendekin alfa inbakicept) is an IL-15 superagonist FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ, combined with BCG. The company also advances investigational NK-cell platforms (haNK, taNK, ceNK, NK-92), QUILT combination clinical programs, and the Nant Cancer Vaccine candidates.

Product overview

ImmunityBio (operating under the NantKwest trademark) is a biopharmaceutical company developing immunotherapies through a platform approach. The core product is ANKTIVA® (nogapendekin alfa inbakicept), an IL-15 superagonist that activates both innate (NK cells) and adaptive (T cells) immune responses. This is combined with BCG (including an exclusive Tokyo-strain agreement) in their QUILT clinical programs for bladder cancer. The company also operates an investigational NK Cell Platform (haNK, taNK, ceNK) derived from the NK-92 cell line. The platform employs a 'triangle offense' strategy targeting multiple immune pathways to achieve durable responses in cancer and infectious diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • ANKTIVA®: FDA-approved immunotherapy product (nogapendekin alfa inbakicept) used with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
  • Nant Cancer Vaccine
  • NANT 001
  • NANT XL
  • QUILT
  • haNK
  • taNK
  • ceNK
  • NK-92
  • VivaBioCell
  • Infacell

Products and services

  • ANKTIVA (nogapendekin alfa inbakicept) An IL-15 superagonist biologic that activates natural killer (NK) cells and CD8+ T cells to stimulate innate and adaptive immune responses; FDA-approved for use with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ, and intended for oncology and infectious disease indications.
  • NK Cell Platform (haNK, taNK, ceNK, NK-92) A suite of investigational Natural Killer cell therapy agents — high-affinity (haNK), targeted (taNK), cord blood-derived (ceNK), and the parent NK-92 cell line — designed to enhance innate immune responses against cancer and being investigated across multiple tumor types.
  • QUILT Clinical Program Platform Clinical trial platform combining ANKTIVA with BCG, checkpoint inhibitors, and other agents to evaluate sequential immunotherapy regimens across NMIBC, NSCLC, glioblastoma, lymphoma, ovarian cancer, and other indications.
  • Cell Licensing (NK cell lines to researchers) Licensing of proprietary NK cell lines (haNK, taNK, ceNK, NK-92) to academic and industry researchers for use in independent immuno-oncology research programs.
  • Tokyo-Strain BCG Supply (exclusive U.S. agreement with Japan BCG Laboratory) Exclusive U.S. supply of the Tokyo strain of BCG from Japan BCG Laboratory, used as part of ANKTIVA plus BCG combination therapy for bladder cancer to enhance BCG supply in the United States.
  • Nant Cancer Vaccine (NANT 001, NANT XL) Cancer vaccine product candidates (including NANT 001 and NANT XL) under development by ImmunityBio as part of its immunotherapy pipeline targeting multiple cancer indications.

Quantifiable outcome

  • FDA PDUFA date set for January 6, 2027 for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary disease

Companies that use NantKwest

Customer profile

Segments8 records

Ideal customer profiles3 records

NantKwest technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

NantKwest partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Japan BCG LaboratorycoreStrategic or Co-development PartnerImmunityBio signed an exclusive U.S. agreement with Japan BCG Laboratory for the Tokyo-strain of BCG to enhance BCG supply in the United States. This partnership addresses supply chain needs for their ANKTIVA plus BCG combination therapy for bladder cancer.

Recent moves6 records

Expansion highlights6 records

NantKwest competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

NantKwest social profiles

Digital presence

NantKwest financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NantKwest leadership team

Management profile

Number of profiles

Profiles1 record

NantKwest funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NantKwest M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NantKwest

What does NantKwest do?

ImmunityBio (operating under the NantKwest trademark) develops and commercializes immunotherapies for cancer and infectious diseases. Its lead product ANKTIVA (nogapendekin alfa inbakicept) is an IL-15 superagonist FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ, combined with BCG. The company also advances investigational NK-cell platforms (haNK, taNK, ceNK, NK-92), QUILT combination clinical programs, and the Nant Cancer Vaccine candidates.

Is NantKwest a public or private company?

NantKwest is a private company. It is classified as corporate owned and is currently operating.

When was NantKwest founded?

NantKwest was founded in 2002. It employs 11 to 50 people.

Where is NantKwest based?

NantKwest is headquartered in Culver City, United States, in the North America region.

Does NantKwest have an API?

No public API is recorded for NantKwest.

What industry is NantKwest in?

NantKwest's product category is Biopharmaceutical Immunotherapy. Its primary akta.pro industry code is HLAAABAD, NK Cell Therapies, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LA Business JournalImmunityBio Shares Swoon After MergerImmunityBio's shares fell 70% after its merger with NantKwest, dropping from $38.70 to $11.39 per share. The company reported no negative news, but its Covid-19 vaccine trials are not ready for widespread distribution until next year. Founder Patrick Soon-Shiong lost nearly $8.6 billion in stake value.LA Business JournalImmunityBio, NantKwest Complete MergerNantKwest shareholders approved a stock-for-stock merger with ImmunityBio, completing the deal. The combined company trades on Nasdaq as IBRX, with shares rising 37% over two days. The merger combines two immunotherapy platforms, leaving 13 drugs in clinical trials.BenzingaNantKwest/ImmunityBio's COVID-19 Vaccine Candidate To Be Tested For Oral And Sublingual Route Of AdministThe FDA has approved the expansion of Phase 1 clinical trials for ImmunityBio Inc's COVID-19 vaccine candidate to include sublingual and oral administration routes, enrolling an additional 105 participants in U.S. trials. The oral and sublingual formulations are designed to address cold-chain distribution challenges and generate mucosal IgA antibody barriers in the upper respiratory tract where the virus first enters the body. Both trials are anticipated to begin this month, with ImmunityBio and merger partner NantKwest (NASDAQ: NK) proceeding toward a combined entity focused on oncology and infectious disease.PR NewswireRM LAW Announces Investigation of NantKwest, Inc.RM LAW, P.C. announced an investigation into potential breaches of fiduciary duty by NantKwest, Inc.'s board of directors concerning the company's agreement to merge with ImmunityBio, Inc. The law firm claims that under the merger terms announced on December 21, 2020, NantKwest shareholders will own only approximately 28% of the combined company following the stock-for-stock transaction. The investigation focuses on whether the board failed to act in shareholders' best interests during the sale process.PR NewswireThinking about buying stock in Express, Nantkwest, Gevo, Canopy Growth Corp, or Chembio Diagnostics?InvestorsObserver issued critical PriceWatch Alerts for the stocks of Express (EXPR), Nantkwest (NK), Gevo (GEVO), Canopy Growth Corp (CGC), and Chembio Diagnostics (CEMI). The alerts are based on a proprietary scoring methodology that evaluates short-term technical, long-term technical, and fundamental factors to determine investment suitability. The article serves as a promotional announcement directing investors to view specific scores via provided links.BenzingaThe Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On GuidancThis article provides a roundup of recent developments in the biotech sector, highlighting key corporate actions such as Alexion pausing a late-stage COVID-19 study and NantKwest reporting positive results for a pancreatic cancer therapy. It also covers financial updates, including revenue preannouncements from Organogenesis and Apyx Medical, alongside regulatory designations and capital offerings by various companies.BenzingaNantKwest Reports Positive Interim Data In Pancreatic Cancer Trials, Stock SoarsNantkwest Inc reported positive interim data from its QUILT 88 metastatic pancreatic cancer trial, showing median survival rates more than doubled compared to historical controls using PD-L1 t-haNK protocols combining natural killer and T-cell therapy without high-dose chemotherapy. In a 12-patient study, 83% of enrolled patients with second-line or greater pancreatic cancer remain alive to date. The company, which completed a reverse-merger with privately-held ImmunityBio in December 2020, plans to list under the ticker symbol 'IBRX' on Nasdaq, with shares surging 19.1% following the announcement.PR NewswireWeissLaw LLP Reminds RNET, NK, HMSY, and QEP Shareholders About Its Ongoing InvestigationsWeissLaw LLP announced ongoing investigations into four separate merger transactions for potential breaches of fiduciary duty by the boards of directors involved. The investigations cover RigNet's merger with Viasat, NantKwest's reverse merger with ImmunityBio, HMS Holdings' acquisition by Gainwell Technologies, and QEP Resources' acquisition by Diamondback Energy. The law firm is reaching out to shareholders of these companies to discuss their rights regarding the proposed transactions.LA Business JournalImmunityBio, NantKwest Deal Boosts Immunotherapy PlatformNantKwest and ImmunityBio announced a stock-for-stock merger on Dec. 21, with the combined company expected to be named ImmunityBio Inc. and trade on Nasdaq under ticker IBRX. ImmunityBio shareholders will receive 0.819 NantKwest shares per share, retaining 72% ownership. The deal aims to combine their immunotherapy platforms, with 13 drugs in clinical trials.PR NewswireSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of NantKwest, Inc. - NKMonteverde & Associates PC is investigating NantKwest, Inc. regarding its proposed merger with ImmunityBio, which involves ImmunityBio shareholders receiving shares of NantKwest. The investigation centers on whether NantKwest and its Board of Directors violated securities laws and failed to conduct a fair process in valuing the proposed transaction. The firm's exploration into this case signifies potential fiduciary duty concerns that could affect shareholders' interests.